Answers are grounded in this paper and cite their sources.
Figure S2. (A) CoMut plot demonstrating TCGA subtype, tumor mutational burden, mutational signature enrichment and mutational profiles of key driver genes for all patient samples at baseline in the reported clinical trial. (B) PD-L1 expression for each patient sample at baseline in the reported clinical trial.
No takes yet. Share an insight, caveat, or question.
An et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: